Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18157282 | 0.79 | NAAA (0.46) | NAAALMNAFAAHCNR1CNR2 | |
| SCHEMBL21850322 | 0.78 | NAAA (0.32) | NAAALMNAFAAHCNR1CNR2 | |
| SCHEMBL9696027 | 0.77 | FAAH (0.53) | NAAALMNAFAAHCNR1CNR2 | |
| SCHEMBL7205921 | 0.75 | NAAA (0.52) | NAAALMNAFAAHCNR1CNR2 | |
| SCHEMBL19336150 | 0.70 | USP2 (0.39) | NAAAMAPTCES2MAPK1 | |
| SCHEMBL223952 | 0.70 | TDP1 (0.36) | NAAA | |
| SCHEMBL3024887 | 0.70 | LMNA (0.54) | LMNAMAPTALDH1A1MAPK1DGKA | |
| SCHEMBL26010979 | 0.69 | MEN1 (0.33) | LMNAFAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL11290293 | 0.69 | TDP1 (0.58) | NAAALMNAFAAHCNR1CNR2 | |
| SCHEMBL17377694 | 0.69 | LMNA (0.57) | LMNAMAPTALDH1A1MAPK1DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675240-B2 | Transdermal cannabinoid formulations | MM TECHNOLOGY HOLDINGS, LLC (US) | 2020-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675240-B2 | Transdermal cannabinoid formulations | TNNC1, CNR2, TNNT2 | NAAA 781/4885LMNA 1410/4885FAAH 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.